20/20 BioLabs Lists on Nasdaq Awaiting FDA Approval
The diagnostics firm enters public markets as it works to secure clinical clearance for its home-based cancer screening tests.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Would you use home-collection laboratory tests to screen for chronic diseases and cancer?
Gaithersburg-based 20/20 BioLabs, formerly known as 20/20 GeneSystems, obtained a direct listing on the Nasdaq stock market under the ticker AIDX in February 2026. The company specializes in home-collection disease screening tests that are currently awaiting FDA approval.
Why it matters
The company’s shift to public markets reflects a strategy of leveraging existing blood test platforms and machine learning analytics to expedite development. This transition arrives as public health initiatives, such as recent state funding for cancer screenings, gain momentum in Maryland.
The firm utilizes blood tests paired with microneedle patches to gather samples from arm capillaries, subsequently applying machine learning to analyze existing biomarker data. These proprietary analytics are designed to integrate with established laboratory infrastructure.
The players
20/20 BioLabs
A Gaithersburg-based diagnostics developer creating home-collection screening tests using capillary blood sampling and machine learning.
Nasdaq
The global electronic stock exchange where 20/20 BioLabs listed as AIDX in February 2026.
The details
20/20 BioLabs uses microneedle patches — small, painless skin-applied devices that puncture the outer layer to draw capillary blood — to facilitate home sample collection. This hardware is paired with a proprietary machine learning engine that processes known biomarker data to assist in disease screening. The firm is currently navigating the regulatory process to achieve FDA approval for its OneTest for Cancer product, which remains essential for broader clinical integration.
Timeline
2000: Company founded as 20/20 GeneSystems.
February 2026: 20/20 BioLabs achieved a Nasdaq listing.
March 2026: Maryland fire departments received $520,000 for OneTest screenings.
2028: Medicare begins coverage of approved multi-cancer tests.
The Tech Race
The development aligns with the broader push toward multi-cancer early detection, as the industry prepares for Medicare's coverage mandate starting in 2028. 20/20 BioLabs is working to secure the necessary regulatory clearance to compete within this clinical landscape.
The firm’s home-collection blood tests are not yet available for general clinical use as they lack FDA authorization. Residents and medical systems in Maryland currently see these tools deployed primarily through targeted public funding programs like those for fire departments.
The takeaway
The company’s market debut marks its transition into a new phase of commercial scaling despite its current lack of regulatory approval. Observers should track the firm’s progress toward securing FDA clearance for its OneTest for Cancer platform to see if it meets the requirements for 2028 Medicare reimbursement.
Further reading
For more on the region's diagnostic development, explore our coverage of Biotech.
Source note: This article includes information reported by Bethesda Magazine.
Live Poll
Would you use home-collection laboratory tests to screen for chronic diseases and cancer?
